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Background: Constitutive activation of signal transducer and activator of transcription 3 (STAT3) has been linked
with proliferation, survival, invasion and angiogenesis of a variety of human cancer cells, including hepatocellular
carcinoma (HCC). Thus, novel agents that can suppress STAT3 activation have potential for both prevention and
treatment of HCC. Here we report, garcinol, a polyisoprenylated benzophenone, could suppress STAT3 activation in
HCC cell lines and in xenografted tumor of HCC in nude mice model.
Experimental design: Different HCC cell lines have been treated with garcinol and the inhibition of STAT3
activation, dimerization and acetylation have been checked by immunoblotting, immuno-fluorescence, and DNA
binding assays. Xenografted tumor model has been generated in nude mice using HCC cell line and effect of
garcinol in the inhibition of tumor growth has been investigated.
Results: Garcinol could inhibit both constitutive and interleukin (IL-6) inducible STAT3 activation in HCC cells.
Computational modeling showed that garcinol could bind to the SH2 domain of STAT3 and suppress its
dimerization in vitro. Being an acetyltransferase inhibitor, garcinol also inhibits STAT3 acetylation and thus impairs its
DNA binding ability. The inhibition of STAT3 activation by garcinol led to the suppression of expression of various
genes involved in proliferation, survival, and angiogenesis. It also suppressed proliferation and induced substantial
apoptosis in HCC cells. Remarkably, garcinol inhibited the growth of human HCC xenograft tumors in athymic
nu/nu mice, through the inhibition of STAT3 activation.
Conclusion: Overall, our results suggest that garcinol exerts its anti-proliferative and pro-apoptotic effects through
suppression of STAT3 signaling in HCC both in vitro and in vivo.
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Hepatocellular carcinoma (HCC) is the most frequent
subtype of liver cancer and third leading cause of mortality
worldwide, which results from poor prognosis [1-3]. More
than 80% of HCC patients are presented at advanced stages* Correspondence: dr.johnluk@gmail.com; tapas.jnc@gmail.com
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reproduction in any medium, provided the orof disease where surgical resection is difficult and other
treatments such as chemotherapy are primarily palliative
[4,5]. Thus, a great challenge lies ahead in identifying novel
treatment regimens to overcome chemoresistance and
prolong the life of HCC patients.
The family of STAT signaling proteins, consisting of seven
members, is involved in important cell signaling events es-
pecially cytokine induced signal transduction pathway [6,7].
Among the various STAT family members, STAT3 has
been most closely linked to tumorigenesis [8,9]. Persistent
activation of STAT3 has been frequently observed in many
kinds of tumors [8,9] including HCC [10-12] and thisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the process of oncogenesis by modulating the expres-
sion of various genes required for tumor cell survival
(e.g., Bcl-xL, Mcl-1, survivin), proliferation (e.g., cyclin
D1, c-Myc), and angiogenesis (e.g., vascular endothelial
growth factor [VEGF]) as well as metastasis [8]. Thus, the
targeted inhibition of STAT3 signaling pathway may pro-
vide significant therapeutic benefits to HCC patients.
Upon activation by cytokines (like IL-6) or growth factors
(such as EGF, PDGF), STAT3 undergoes phosphorylation-
induced homodimerization or heterodimerization, which
in turn results in the nuclear translocation, DNA bind-
ing, and subsequent modulation of gene transcription.
STAT3 phosphorylation can be mediated through the
activation of upstream non–receptor protein tyrosine kin-
ase family of Janus-like kinase (JAKs), and c-Src kinase [6].
STAT3 also gets acetylated by p300 at lysine 685 which is
essential to form stable dimers [13]. Acetylated STAT3
binds strongly to the DNA, enhances transcription of genes
essential for cell growth and thus contributes towards
tumorigenesis. Acetylation of STAT3 is elevated in tumors
and contributes towards tumor progression by inducing
DNA methylation at the promoters of tumor suppressor
genes [14]. Thus, targeting acetylation of STAT3 using
small molecule approach could be a potential means for
chemoprevention and cancer therapy.
In the present report, we analyzed the effect of garcinol, a
natural polyisoprenylated benzophenone, isolated from the
dried rind of the fruit Garcinia indica, which has attracted
great attention of late for its potential anti-cancer effects
[15-17]. Garcinol is a potent inhibitor of acetyltransferase
activity of p300 and PCAF and inhibits transcription
from chromatin template [15]. Garcinol has been re-
ported to inhibit the proliferation and induce apoptosis
in different tumor cells in vitro [16-19], and also exhibit
potent anti-oxidant, anti-inflammatory and bactericidal
activities [20-22]. The ability of garcinol to modulate
the expression of pro-inflammatory cytokines, inducible
nitric oxide synthase (iNOS) and cyclooxygenase-2, NF-κB,
STAT3, Akt, FAK, death receptors, nicotinic receptors, cyc-
lin D3, and histone acetyltransferases (p300 and PCAF) has
been reported [23-28]. However, the potential anti-cancer
effects of garcinol in HCC cancer model and in the context
of STAT3/JAK2 signaling cascade as well as STAT3 acetyl-
ation have not been investigated yet.
Because of the critical role of STAT3 in HCC survival,
proliferation, invasion, and angiogenesis [29,30], we inves-
tigated whether garcinol can mediate its anti-proliferative
and pro-apoptotic effects in HCC cells through the sup-
pression of the STAT3 pathway. We found that garcinol
can indeed suppress both constitutive as well as inducible
STAT3 activation through blocking its dimerization, nu-
clear transport and DNA binding by inhibiting its phos-
phorylation and acetylation. This inhibition decreased cellsurvival and downregulated expression of proliferative,
anti-apoptotic and angiogenic gene products, leading to
suppression of proliferation and the induction of apoptosis
in HCC cells. Garcinol also inhibited the growth of human
HCC cells in a xenograft mouse model and modulated the
activation of STAT3 in the tumor tissues.Results
The polyisoprenylated benzophenone, garcinol is a potent
natural compound, able to target multiple protein/enzymes
thereby different pathways in the cellular system. These
properties and the scaffold of garcinol have made garcinol
an attractive molecule for anti-neoplastic therapeutics.
We have investigated the effect of garcinol on constitutive
and inducible STAT3 activation in HCC cells. We also
have evaluated the effect of garcinol on various mediators
of cellular proliferation, cell survival, and apoptosis. The
structure of garcinol is shown in Figure 1A.Garcinol suppresses nuclear translocation of STAT3 and
its phosphorylation
As nuclear translocation is central to the function of
transcription factors [31], we intended to determine
whether garcinol can modulate nuclear translocation
of STAT3 and thereby affect its transcriptional role in
cell. Interestingly, garcinol treatment inhibited the
translocation of STAT3 to the nucleus in HCC cells as
evident in our immunofluorescence assay (Figure 1B,
Additional file 1: Figure S1, Additional file 2: Figure S2).
Further, the ability of garcinol to modulate constitutive
STAT3 activation in HCC cells was investigated. C3A
cells were incubated with different concentrations of
garcinol for 6 h, whole cell extracts were prepared and
the phosphorylation of STAT3 was examined by Western
blot analysis using antibodies which recognize STAT3
phosphorylation at tyrosine 705. Garcinol was found to in-
hibit the constitutive activation of STAT3 in C3A cells in
a dose and time dependent manner as indicated by de-
creased phosporylated form of STAT3 in our immuno-
blotting experiment (Figure 1C and D). In dose dependent
inhibition assay, maximum inhibition was observed at
50 μM concentration. The 50 μM garcinol could inhibit
maximally the STAT3 phosphorylation at around 4–6 h of
treatment. In JAK-STAT pathway, JAK2 is the kinase re-
sponsible for the phosphorylation of tyrosine 705 residue
on STAT3. So, we wanted to verify the same under our ex-
perimental conditions with pharmacological modulation
approach. To determine the effect of garcinol on JAK2 ac-
tivation, C3A cells were treated for different time intervals
with garcinol and phosphorylation of JAK2 was analyzed
by Western blot. As shown in Figure 1E, JAK2 was consti-
tutively active in C3A cells and pre-treatment with garci-
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Figure 1 Garcinol reduces the constitutively active form of STAT3. (A) The chemical structure of garcinol. (B) Garcinol causes inhibition of
translocation of STAT3 to the nucleus in C3A cells. (C) Garcinol suppresses phospho-STAT3 (Tyr 705) levels in a dose dependent manner. C3A cells
(2×106/ml) were treated with the indicated concentrations of garcinol for 6 h, and the whole cell extract was subjected to western blotting
analysis using phospho-STAT3 antibody. (D) Garcinol suppresses phospho-STAT3 levels in a time-dependent manner. C3A cells (2×106/ml) were
treated with the 50 μM garcinol for the indicated times, after which western blotting was performed as described for panel C. The same blots
were stripped and reprobed with STAT3 antibody to verify equal protein loading. (E) C3A cells (2×106/ml) were treated with the 50 μM garcinol
for the indicated times, after which western blotting was performed against phospho-JAK2 antibody. The same blots were stripped and reprobed
with JAK2 antibody to verify equal protein loading. (F) IL-6 induces phosphorylation of STAT3 in a dose dependent manner. HUH-7 cells
(2×106/ml) were treated with indicated concentrations of IL-6 (10 ng/ml) for 15 min and the whole-cell extracts were subjected to western
blotting analysis. (G) Garcinol downregulates IL-6–induced phospho-STAT3 in HUH-7 cells. HUH-7 cells (2×106/ml) were treated with 50 μM
garcinol for the indicated durations and then stimulated with IL-6 (10 ng/ml) for 15 min and the whole-cell extracts were subjected to western
blotting analysis. (H) Garcinol did not affect phospho-STAT3 (Ser727) levels in C3A cells. C3A cells (2×106/ml) were treated with the indicated
concentrations of garcinol for 6 h, and the whole cell extract was subjected to immune-blotting analysis using phospho-STAT3 (Ser727) antibody.
The same blots were stripped and reprobed with STAT3 antibody to verify equal protein loading.
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JAK2 kinase and inhibits the phosphorylation of STAT3.
Activation of STAT3 via phosphorylation has been
demonstrated to be induced in response to various cyto-
kines such as IL6 [32,33]. To investigate whether garcinolcould modulate cytokine-induced STAT3 phosphoryl-
ation, HUH-7 cells (which have low levels of endogenous
constitutively active STAT3) were activated with IL-6 and
consequently effect of garcinol treatment was checked.
Activation of STAT3 phosphorylation by IL-6 treatment
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Garcinol (50 μM) treatment for different time durations
on IL-6 activated HUH-7 cells substantially suppressed
STAT3 phosphorylation in a time-dependent manner
(Figure 1G). Because STAT3 also undergoes phosphoryl-
ation at Ser 727, we next investigated whether garcinol
has an effect on this phosphorylation. Interestingly, we
found that garcinol had minimal effect on the STAT3
activation at Ser 727 residue, thereby suggesting that it
specifically blocks tyrosine phosphorylation of STAT3
in C3A cells (Figure 1H). Collectively, these data indicate
that garcinol suppresses STAT3 tyrosine phosporylation,
thereby inhibiting its nuclear localization.
Garcinol inhibits STAT3 dimerization via physical
interaction as well as inhibition of acetylation
STAT3 is a 770 amino acid long protein and the
dimerization domain is positioned on its C-terminus
(Figure 2A). STAT3 dimerization occurs through the
interaction of the SH2 domain on one STAT3 molecule
with a loop segment (from Ala702 to Phe716) on the other
STAT3 monomer [34]. The phosphorylated Tyr705 on
one STAT3 molecule is a critical residue for binding to
a cavity on the SH2 domain of the other STAT3 protein
[35]. To investigate whether garcinol can bind to the
STAT3 SH2 domain, computational modeling was per-
formed. The crystal structure of STAT3 at 2.25- Å reso-
lution [34] was obtained from the Protein Data Bank
(PDB ID code 1BG1) and used for computational dock-
ing analysis. The results of this modeling approach
predicted multiple interactions of Garcinol with amino
acids Ser 614, Gly 617, Glu 638 and Thr 641 on STAT3
(Figure 2B and C). The docking energy was - 4.45 kcal
and inhibition constant was 543.21 μM. The intermolecular
energy, internal energy and torsional energy was - 8.63 kcal,
−3.21 kcal and 4.18 kcal respectively. The residues which
were predicted to interact with garcinol fall in SH2 domain.
SH2 domain being the interacting module for dimerization
of STAT3, we hypothesized that garcinol might interfere
with dimerization of the protein via direct binding. To
experimentally validate the prediction, we transfected
HEK293T cells with FLAG-STAT3 expression mammalian
construct. After 24 h of transfection, cells were harvested
and lysates were prepared in isotonic buffer. Two different
concentrations of garcinol (10 and 25 μM) were incubated
with the lysates (Figure 2D, lanes 4 and 5) and DMSO was
added as the solvent control (Figure 2D, lane 3). We ob-
served that garcinol could inhibit STAT3 dimerization in
a dose dependent manner in vitro suggesting direct inter-
action of STAT3 and garcinol (Figure 2D, compare lane 3
versus lanes 4 and 5). To further validate the inhibition
of STAT3 dimerization in vivo, we treated FLAG-STAT3
transfected HEK293T cells with garcinol (25 μM) and per-
formed a native PAGE using the whole cell lysate andobserved that garcinol could efficiently reduce the levels of
dimer form of STAT3 in mammalian cells as well, which is
consistent with the results, obtained from in vitro experi-
ments (Figure 2E).
Apart from phosphorylation, acetylation of STAT3 also
plays pivotal roles in its dimerization, DNA binding and
promotion of tumorigenesis [13,14,36]. Overexpression of
lysine acetyltransferases such as p300 has been documented
in various cancers including HCC cells [37,38]. As garcinol
is a well known lysine acetyltransferase inhibitor, we ex-
plored the possibility of inhibition of STAT3 acetylation by
garcinol. We observed that garcinol could efficiently inhibit
STAT3 acetylation in sodium butyrate pretreated HepG2
cells (Figure 2F). The dimer form of STAT3 is the most ac-
tive form that has the ability to bind on the promoters of
its target genes. The dimerization ability of STAT3 depends
upon its phosphorylation and acetylation status [13]. Since
garcinol inhibits both the acetylation and phosphorylation
of STAT3 and furthermore presumably binds directly at the
dimerization domain, garcinol treatment would inhibit the
DNA binding of STAT3. We performed a DNA binding
assay using oligonucleotides derived from c-fos promoter
containing STAT3 binding site for this purpose. FLAG-
STAT3 construct was transfected in HEK293T cells for
24 h and FLAG tagged STAT3 was pulled down using
immunoaffinity chromatography and was used for EMSA.
The DNA binding ability of STAT3 seemed to be abrogated
because of inhibition of dimerization with incubation of gar-
cinol in vitro which further led to concomitant increase in
weak interaction of STAT3 monomer with the target DNA.
This suggests the potential of garcinol to inhibit binding
ability of STAT3 to its target promoters (Figure 2G).
Garcinol suppresses STAT3 dependent transcription and
downregulates the expression of cyclin D1, Bcl-2, Bcl-xL,
Mcl-1, survivin, and VEGF thereby affecting cell cycle
progression as well as cell viability
Our above results showed that garcinol perturbed phos-
phorylation and acetylation and also nuclear translocation
of STAT3. As these are the key events dictating functional
behavior of STAT3, we next determined whether garcinol
affects STAT3-dependent gene transcription. When PLC/
PRF5 cells, transiently transfected with the pSTAT3-Luc
construct, were stimulated with EGF, STAT3-mediated
luciferase gene expression was found to be substantially
increased. Dominant-negative STAT3 significantly blocked
this increase, indicating specificity. Remarkably, when the
cells were pretreated with garcinol, EGF–induced transcrip-
tional activity of STAT3 was inhibited in a dose-dependent
manner (Figure 3A).
STAT3 activation has been reported to regulate the
expression of various gene products involved in cell sur-
vival, proliferation, angiogenesis and chemoresistance [8].
We found that expression of the cell cycle regulator cyclin
A
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Figure 2 Garcinol docks on to SH2 domain of STAT3 and inhibits STAT3 dimerization and acetylation, thereby preventing its nuclear
localization and DNA binding. (A) Diagrammatic representation of different domains of STAT3. (B) Predicted model of garcinol binding to the
STAT3 SH2 domain as shown by computational docking. Protein structure information was obtained from Protein Data Bank entry 1BG1. Garcinol
shows interaction with residues Ser614, Gly617, Glu638 and Thr641 of STAT3. (C) Surface view of docked garcinol on STAT3 protein surface. (D)
Garcinol inhibits STAT3 dimerization in vitro. Native protein extracts prepared from 293 T cells transfected with FLAG-STAT3 were incubated with
two different concentrations of garcinol for 15 min at 30°C and were loaded in 6% SDS free native PAGE. STAT3 dimers were visualized by
immune-blotting with anti-FLAG antibody. (E) Garcinol inhibits STAT3 dimerization in vivo. 293 T cells transfected with FLAG-STAT3 were treated
with DMSO or garcinol (25 μM) for 3 h and whole cell lysates were prepared. Twenty micrograms of protein per sample was loaded onto a 10%
native PAGE gel, and electrophoresis was performed in the absence of SDS and subjected to immune-blotting analysis. (F) Garcinol inhibits
acetylation of STAT3 in cells in a dose dependent manner. HepG2 cells were incubated with 1 mM sodium butyrate (NaBu) for 6 h followed by
treatment with different doses of garcinol. Cells were lysed in Laemmli buffer and immunoblotting was performed using antibodies against
acetylated STAT3 and total STAT3. (G) Garcinol mediated inhibition of STAT3 acetylation reduces DNA binding ability of STAT3. FLAG-STAT3 was
immuno-affinity purified from HEK293T cells (after transient transfection of FLAG-STAT3 construct for 24 h) and was incubated with garcinol in a
dose dependent manner and EMSA assay was carried out using a 32P-labelled oligo containing STAT3 binding site. For supershift validation, STAT3
antibody was added in lane 3.
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and the angiogenic gene product VEGF all of which have
been reported to be regulated by STAT3 were modulated
by garcinol treatment. Their expression decreased in a
time-dependent manner, with maximum suppression
observed at around 24–36 h (Figure 3B). Since Cyclin
D1 is required for the progression of cells from the G1
phase of the cell cycle to S phase and rapid decline in levels
of cyclin D1 was observed in garcinol treated cells; we
wanted to determine the effect of garcinol on cell cycle
phase distribution. We found that garcinol treatment
caused increased accumulation of cell population in G0/G1
phase of the cell cycle (Figure 3C) when C3A cells were
treated with 25 μM of garcinol for 12 h. Moreover, garcinol
treatment for longer duration (48 h) led to enrichment of
cells in Sub-G1 population, indicating incidence of apop-
tosis. Understandably, cell cycle arrest at G0/G1 phase as
well as incidence of apoptosis would mean reduced cell
proliferation which was reflected in our MTT assay. Garci-
nol inhibited the proliferation of C3A, HUH-7, PLC/PRF5,
and HepG2 cells in a dose and time dependent manner
(Figure 4A). To further validate and confirm that garcinol
mediated inhibition of STAT3 activation is really inducing
apoptosis mediated cell death, thereby contributing to re-
duced proliferation of HCC; C3A cells were treated with
garcinol and checked for pro-caspase and cleaved-caspase
levels in cells. There was a time-dependent activation of
caspase-3 upon garcinol treatment as indicated from de-
crease in levels of pro-caspase 3 and increased levels of
cleaved form of the protein as observed in our immuno-
blotting assay (Figure 4B). Activation of caspase-3 leads to
the cleavage of 116 kDa PARP proteins into an 85 kDa
fragment, which was confirmed in our immunoblotting ex-
periment (Figure 4B). These results clearly suggest that gar-
cinol induces caspase-3-dependent apoptosis in HCC cells.
There have been constant efforts to develop anti-cancer
drugs to fight progression of different tumors in human.
Among various chemotherapeutic agents, doxorubicin, an
anthracycline antibiotic, and paclitaxel, a mitotic inhibitor,have been used for HCC treatment [39]. To look into
druggable nature of garcinol we examined whether garci-
nol can potentiate the effect of these drugs in context of
hepato-cellular carcinoma. C3A cells were treated with
garcinol together with either doxorubicin or paclitaxel,
and then apoptosis was measured by the live/dead assay.
As shown in Figure 4C, garcinol significantly enhanced
the apoptotic effects of paclitaxel from 10% to 35% and
of doxorubicin from 12% to 38% respectively. Thus, our
experimental results suggest that garcinol could act in
combination with other anti-cancer agents to enhance
apoptosis and retard cellular proliferation in HCC, there-
fore, making it amenable for drug development.
Garcinol suppresses the growth of human HCC in vivo
and STAT3 activation in tumor tissues
To investigate the anti-tumor potential of garcinol in vivo,
a subcutaneous model of human HCC was generated in
athymic mice via intra-peritoneal injection of PLC/PRF5
cells. Garcinol at doses of 1 mg/kg and 2 mg/kg induced
significant inhibition of tumor growth compared with the
DMSO-treated controls (Figure 5A). Two-way repeated
measures ANOVA showed a statistically significant differ-
ence in tumor growth between the garcinol-treated and
control groups (Figure 5B). We further evaluated the
effect of garcinol on constitutive p-STAT3 levels in HCC
tumor tissues by immunohistochemical analysis and found
that garcinol substantially inhibited the constitutive STAT3
activation in treated group as compared with control group
(Figure 5C). The effect of garcinol was also analyzed on
the expression of Bcl-2 (marker of survival) and caspase-3
(marker of apoptosis). As shown in Figure 5C, expression
of Bcl-2 was downregulated and that of caspase-3 was
substantially increased in garcinol treated group as
compared with control group, indicating incidence of
cell death via apoptosis.
Taken together, these data suggest that garcinol, being
able to inhibit phosphorylation and acetylation of STAT3,




Figure 3 Garcinol suppresses STAT3 regulated genes involved in proliferation, survival and angiogenesis. (A) Garcinol inhibits EGF–induced
STAT3-dependent reporter gene expression. PLC/PRF5 cells (5 × 105/mL) were transfected with STAT3-luciferase (STAT3-Luc) plasmid, incubated
for 24 h, and treated with indicated doses of garcinol for 4 h and then stimulated with EGF (100 ng/mL) for 2 h. Whole-cell extracts were then
prepared and analyzed for luciferase activity. The results shown are representative of three independent experiments. * indicates p value <0.05.
(B) Garcinol downregulates the expression of cyclin D1, Bcl-2, Bcl-xL, Mcl-1, survivin, and VEGF. C3A cells (2×106/ml) were treated with 25 μM
garcinol for indicated time intervals, after which whole-cell extracts were prepared and 30 μg portions of those extracts were subjected to
western blotting, upon resolving on 10% SDS-PAGE. (C) Garcinol causes accumulation of cells in G0/G1 phase of cell cycle and enrichment in
Sub G1 population. C3A cells (2×106/mL) were treated with 25 μM garcinol for 12 h and 48 h, after which the cells were washed, fixed, stained
with PI, and analyzed for DNA content by flow cytometry.
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of STAT3 and ultimately lead to reduced proliferation
as well as induction of apoptosis in HCC; therefore,
could be exploited as a potential antineoplastic thera-
peutic in HCC.Discussion
The aim of this study was to determine whether garcinol
exerts its anti-cancer effects in HCC cells through the
abrogation of the STAT3 signaling pathway, targeting the
post-translational modification of STAT3 and dimerization
AB
C
Figure 4 Garcinol reduces cellular proliferation and induces apoptosis in HCC cells. (A) Garcinol inhibits proliferation of HCC cells in a dose
and time dependent manner. Different cell lines were plated in triplicate, treated with indicated concentrations of garcinol, and then subjected to
MTT assay after 24, 48 and 72 h to analyze proliferation of cells. Data represents result of three independent experiments. (B) Garcinol promotes
apoptosis: C3A cells were treated with 50 μM garcinol and the whole cell extracts were subjected to immune-blotting with antibodies against pro-
caspase-3, cleaved caspase-3 and PARP taking β-actin as loading control. (C) Garcinol potentiates the apoptotic effect of doxorubicin and paclitaxel.
C3A cells (1×106/ml) were treated with 10 μM garcinol and 10 nM doxorubicin or 5 nM paclitaxel alone or in combination for 24 h at 37°C. Cells were
stained with a Live/Dead assay reagent for 30 min and then analyzed under a fluorescence microscope as described in Materials and Methods.
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http://www.molecular-cancer.com/content/13/1/66of the transcription factor. We found that this benzophe-
none inhibited both constitutive and inducible STAT3
activation in human HCC cells concomitant with the in-
hibition of phosphorylation and acetylation of STAT3
and thereby the dimerization and its DNA binding ability.
As a consequence garcinol further downregulated the
expression of various STAT3-regulated genes including,
cyclin D1, Bcl-2, Bcl-xL, survivin, Mcl-1, and VEGF, caused
the inhibition of proliferation, and induced substantialapoptosis in HCC cells. We subsequently investigated the
therapeutic potential of garcinol in HCC xenograft grown
in mouse model. Intra-peritoneal injection of garcinol into
nude mice bearing subcutaneous PLC/PRF5 xenografts
resulted in significant suppression of tumor progression
and suppression of expression of p-STAT3 in garcinol
treated tumor tissues.
Using computational modeling, we found that garci-
nol may directly bind to the SH2 domain of STAT3.
AB
C
96%                                 5%                            2%
69%                              32%                              2%
2%                               76%                             86%  




Mock      1mg/kg      2mg/kg
Garcinol
Mock    1mg/kg    2mg/kg
Garcinol
Figure 5 Garcinol inhibits the growth of human HCC in vivo. (A) Garcinol treatment reduced the size of tumor induced in nude mice.
Athymic mice bearing subcutaneous PLC/PRF5 tumors were treated for 5 times a week for 4 consecutive weeks with 1 mg/kg and 2 mg/kg
garcinol (n = 5) or corn oil alone (n = 4). Tumor size was measured and compared for different conditions. (B) Reduction in tumor volume upon
garcinol treatment was statistically significant. * = P < 0.001 (One-way ANOVA). (C) Immunohistochemical analysis showed the inhibition in
expression of phospho-STAT3, and Bcl-2 and increased levels of caspase-3 expression in garcinol treated mice tissues as compared with control
group. Percentage indicates positive staining for the given biomarker. The photographs were taken at the magnification of × 20.
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action through which garcinol interacts with amino acids
Ser 614, Gly 617, Glu 638 and Thr 641 residues of STAT3.
These observations suggested that garcinol may inhibitthe dimerization of STAT3 through its interaction with
the SH2 pocket of STAT3. By employing high-throughput
screening, recently, another natural compound- crypto-
tanshinone, a benzofuran, has been identified, which also
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hibit its dimerization [40]. Our finding does strengthen
this hypothesis further that the systemic blocking of
STAT3 dimerization through the small molecule mediated
intervention could be a useful tool to suppress the consti-
tutive activation of STAT3. However, unlike garcinol, the
cryptotanshinone inhibit the STAT3 phosphorylation in a
JAK2 independent manner [14]. We observed that garci-
nol could also suppress IL-6 -induced STAT3 activation in
HCC cells and these effects of garcinol correlated with the
suppression of upstream protein tyrosine kinase JAK2 au-
tophosphorylation. Previous studies have indicated that
the IL-6/ gp130/JAK signaling pathway can phosphorylate
STAT3 Tyr705 in various tumor cells, including HCC
[41,42]. We also observed that garcinol suppressed
nuclear translocation of STAT3 and induction of EGF-
induced reporter activity by STAT3.
Apart from the phosphorylation, STAT3 is also sub-
jected to acetylation which is pivotal for its stable dimer
formation and sequence specific DNA binding [13,36].
Furthermore, HCC is also associated with hyperacetyla-
tion of histones and non-histone proteins, which con-
tributes to the cancer progression. In consistent with the
previous reports about garcinol and its acetyltransferase
inhibitory activity [43,44]; we observed that garcinol
could effectively inhibit STAT3 acetylation in a dose
dependent manner. Our studies indicated that inhibition
of STAT3 acetylation impaired its nuclear localization
and DNA binding. This suggests that garcinol could
manifest its effect on STAT3 activation through multiple
mechanism(s) especially by inhibiting phosphorylation
and acetylation of STAT3 and directly binding to its
SH2 domain.
STAT3 phosphorylation plays a crucial role in prolifer-
ation and survival of tumor cells. Various types of can-
cer, including head and neck cancers [45] multiple
myeloma [46], lymphomas, and leukemia [47], also have
constitutively active STAT3. The suppression of consti-
tutively active STAT3 in HCC cells raises the possibility
that garcinol might also suppress constitutively activated
STAT3 in other types of cancer cells. Previously, it has
been reported that garcinol can suppress NF-κB activa-
tion in the breast and pancreatic cancer cells [28,48].
Interestingly, a recent report indicated that STAT3 can
prolong NF-κB nuclear retention through acetyltransfer-
ase p300-mediated RelA acetylation, thereby interfering
with NF-κB nuclear export [49]. Thus, garcinol mediated
inhibition of acetyltransferase activity, as well as STAT3
phosphorylation by JAK2 may synergistically affect tran-
scriptional activity of NF-κB and thereby act as an anti-
neoplastic compound.
We also observed that garcinol can suppress the expres-
sion of several STAT3-regulated genes; including prolifera-
tive (cyclin D1), antiapoptotic genes (Bcl-2, Bcl-xL, survivin,and Mcl-1) and angiogenic gene (VEGF). The downregula-
tion of the expression of Bcl-2, Bcl-xL, survivin and Mcl-1
is likely linked with the garcinol’s ability to induce apop-
tosis in HCC cells as clearly evident by activation of pro-
caspase-3 and cleavage of PARP. The down modulation of
VEGF expression as reported here may also explain the
anti-angiogenic potential of this benzophenone but needs
further investigation.
Whether these in vitro observations with garcinol have
any relevance to the in vivo scenario was also investi-
gated. Our results clearly showed that garcinol signifi-
cantly suppressed HCC growth in nude mouse model,
downregulated the expression of phospho-STAT3 and
Bcl-2, and increased the levels of caspase-3 in treated
group as compared to control group. Additionally, we
did not notice any observable adverse effects in animals
following treatment with garcinol although we did not
perform a detailed preclinical toxicological analysis in
this study. Moreover, to the best of our knowledge, no
prior studies with garcinol in xenograft HCC models
have been reported so far, and our overall findings
suggest that garcinol has a tremendous potential to
serve as a lead molecule for the treatment of HCC
through the modulation of STAT3 activation pathway.
Two recent reports on garcinol mediated inhibition of
growth of xenografted tumor developed from different
cancer sources in the context of STAT3 function fur-
ther underscore the therapeutic implications of garci-
nol [45,50].
Garcinol has been shown to be well tolerated in pre-
clinical studies using various cancer models, with no re-
ported toxicity so far [51-53]. Garcinol as such has never
been tested in humans before and hence its clinically
relevant doses are not known as yet. Thus, overall, our
in vitro and in vivo findings clearly demonstrate that the
anti-proliferative and apoptotic effects of garcinol in
HCC are mediated through suppression of STAT3 acti-
vation and provide a sound basis for pursuing the use of
garcinol to overcome toxicity and enhance treatment ef-
ficacy for HCC patients.Conclusion
Our results show that garcinol could suppress constitutive
and inducible activation of STAT3 in HCC. Garcinol could
inhibit STAT3 phosphorylation and acetylation, thereby
prevent its dimerization as well as nuclear localization. As a
consequence garcinol further led to downregulation of ex-
pression of various STAT3-regulated genes including, cyclin
D1, Bcl-2, Bcl-xL, survivin, Mcl-1, and VEGF and caused
the inhibition of proliferation and induced substantial apop-
tosis in HCC cells. Finally, garcinol suppressed growth of
HCC in xenograft mice model, underscoring its importance
as an anti-cancer therapeutic agent.
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Reagents
Garcinol with purity greater than 98% was prepared from
Garcinia indica fruit rind as described previously [15]. A
50 mM stock solution of garcinol was prepared in dimethyl
sulfoxide and stored at −20°C to be used within 3 months
after preparation. The stored solution was diluted with
RPMI 1640 medium and further diluted in cell culture
medium to make working concentrations. Hoechst 33342,
MTT, Tris, glycine, NaCl, SDS, BSA, and EGF were
purchased from Sigma-Aldrich (St. Louis, MO). RPMI
1640, fetal bovine serum (FBS), 0.4% trypan blue vital
stain, and antibiotic-antimycotic mixture were obtained
from Invitrogen (Carlsbad, CA, USA). Rabbit polyclonal
antibodies against STAT3 and mouse monoclonal anti-
bodies against phospho- STAT3 (Tyr 705), STAT3 (Ser
727), Bcl-2, Bcl-xL, cyclin D1, survivin, Mcl-1, VEGF,
caspase-3, cleaved caspase-3, and PARP were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
bodies for phospho-specific JAK2 (Tyr 1007/1008) and
JAK2 were purchased from Cell Signaling Technology
(Beverly, MA). FLAG antibody was purchased from Sigma-
Aldrich (St. Louis, MO). Acetylated STAT3 (Lys-685) anti-
body was obtained from Thermo Scientific Pierce (Thermo
Scientific Pierce, USA). Goat anti-rabbit-horse radish
peroxidase (HRP) conjugate and goat anti-mouse HRP
were purchased from Sigma-Aldrich (St. Louis, MO).
Bacteria-derived recombinant human IL-6 was pur-
chased from ProSpec-Tany TechnoGene Ltd. (Rehovot,
Israel).
Cell lines
Human hepatocellular carcinoma cell lines (C3A, HepG2,
PLC/PRF5, and HUH-7) were obtained from American
Type Culture Collection (Manassass, VA). C3A, HepG2,
and HUH-7 cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) containing 1 X antibiotic-antimycotic
solution with 10% FBS. PLC/PRF5 cells were cultured
in DMEM containing 1x penicillin-streptomycin solu-
tion, non-essential amino acids, sodium pyruvate, and
L-glutamine with 10% FBS. HEK293T also obtained from
ATCC cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) containing 1 X antibiotic streptomycin
solution, sodium pyruvate with 10% FBS.
Western blotting
For detection of phopho-proteins, garcinol-treated whole-
cell extracts were lysed in lysis buffer (20 mM Tris (pH 7.4),
250 mM NaCl, 2 mM EDTA (pH 8.0), 0.1% Triton X-100,
0.01 mg/ml aprotinin, 0.005 mg/ml leupeptin, 0.4 mM
PMSF, and 4 mM NaVO4). Lysates were then spun at
14,000 rpm for 10 min to remove insoluble material and
resolved on a 7.5% SDS-PAGE gel. After electrophoresis,
the proteins were electrotransferred to a nitrocellulosemembrane, blocked with Blocking One (Nacalai Tesque,
Inc.), and probed with various phospho-antibodies
(1:1000) overnight at 4°C. The blot was washed, exposed
to HRP-conjugated secondary antibodies for 1 h, and
finally examined by chemiluminescence (ECL; GE Health-
care, Little Chalfont, Buckinghamshire, UK).
To detect STAT3-regulated proteins, caspase-3 and
PARP, C3A cells (2×106/ml) were treated with garcinol
for the indicated time. The cells were then washed and
the protein was extracted by incubation for 30 min on ice
in 0.05 ml buffer containing 20 mM HEPES, pH 7.4, 2 mM
EDTA, 250 mM NaCl, 0.1% NP-40, 2 μg/ml leupeptin, 2
μg/ml aprotinin, 1 mM PMSF, 0.5 μg/ml benzamidine,
1 mM DTT, and 1 mM sodium vanadate. The lysate was
centrifuged and the supernatant was collected. Whole-cell
extract protein (30 μg) was resolved on 12% SDS-PAGE,
electrotransferred onto a nitrocellulose membrane, blotted
with various antibodies and then detected by chemilu-
minescence (ECL; GE Healthcare, Little Chalfont, Buck-
inghamshire, UK). The densitometric analysis of
scanned blots was done using Image J software and the
results are expressed as fold change relative to the control.
Immunocytochemistry for STAT3 localization
C3A cells were plated in chamber slides in DMEM contain-
ing 10% FBS and allowed to adhere for 24 h. On next day,
following treatment with garcinol for 4 h, the cells were fixed
with cold acetone for 10 min, washed with PBS and blocked
with 5% normal goat serum for 1 h. The cells were then in-
cubated with rabbit polyclonal anti-human STAT3 antibody
(dilution, 1/100). After overnight incubation, the cells were
washed and then incubated with goat anti-rabbit IgG-Alexa
594 (1/100) for 1 h and counterstained for nuclei with
Hoechst (50 ng/ml) for 5 min. Stained cells were mounted
with mounting medium (Sigma-Aldrich) and analyzed under
an fluorescence microscope (Olympus DP 70, Japan).
Docking analysis
The Mus musculus STAT3 Protein structure (UniProtKB/
Swiss-Prot id P42227) was downloaded from PDB, (PDB
id 1bg1) having resolution 2.25 Å. It is a phosphorylated
monomer structure with chain A (consisting of 558 amino
acids: 136–716), which is complexed with a DNA chain
(designated as chain B). The DNA chain was removed from
the complex while preparing this molecule for docking.
Protein was prepared in Autodock 1.5.4. The water
molecules and DNA binding structure were removed and
then polar hydrogen and Gasteiger charges were added
to it. Grid box was prepared at its SH2 domain having
dimensions - X:116, Y: 82 and Z: 122., keeping the grid
spacing at 0.375. Coordinate file of ligand garcinol was
created using Gaussian 03 program. The ligand was then
prepared using Autodock 1.5.4 tool, where Gasteiger
charges and polar hydrogen were added and number of
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STAT3 luciferase reporter assay
PLC/PRF5 cells were plated in ninety six-well plates with 1
x 104 per well in DMEM containing 10% FBS. The STAT3-
responsive elements linked to a luciferase reporter gene
were transfected with wild-type STAT3 or dominant-
negative STAT3-Y705F (STAT3F). These plasmids were a
kind gift from Dr. Bharat B. Aggarwal at M D Anderson
Cancer Center, Houston, TX. Transfections were done ac-
cording to the manufacturer's protocols using Fugene-6 ob-
tained from Roche (Indianapolis, IN). At 24 h post-
transfection, cells were pretreated with garcinol for 4 h and
then induced by EGF for additional 2 h before being
washed and lysed in luciferase lysis buffer from Promega
(Madison, WI, USA). Luciferase activity was measured with
a luminometer by using a luciferase assay kit (Promega)
and was normalized to β-galactosidase activity. All lucifer-
ase experiments were done in triplicate and repeated three
or more times.
MTT assay
The anti-proliferative effect of garcinol against HCC
cells was determined by the MTT dye uptake method as
described previously [11]. Briefly, the cells (5x103/ml) were
incubated in triplicate in a 96-well plate in the presence or
absence of indicated concentration of garcinol in a final
volume of 0.2 ml for different time intervals at 37°C.
Thereafter, 20 μl of MTT solution (5 mg/ml in PBS) was
added to each well. After a 2-h incubation at 37°C, 0.1 ml
of lysis buffer (20% SDS, 50% dimethylformamide) was
added; incubation was continued overnight at 37°C; and
then the optical density (OD) at 570 nm was measured
by Tecan plate reader.
Live/Dead assay
Apoptosis of cells was determined by Live/Dead assay kit
(Life technologies, Carlsbad, USA) that measures intracel-
lular esterase activity and plasma membrane integrity as
described previously [11]. Briefly, 1 X106 cells were incu-
bated with garcinol/doxorubicin/ paclitaxel alone or in
combination for 24 h at 37°C. Cells were stained with
the Live/Dead reagent (5 μM ethidium homodimer, 5
μM calcein-AM) and then incubated at 37°C for 30 min.
Cells were analyzed under a fluorescence microscope
(Olympus DP 70, Japan).
Cell cycle analysis
To determine the effect on the cell cycle, C3A cells were
treated with garcinol (25 μM) for 12 h and 48 h. There-
after cells were washed, fixed with 70% ethanol. Cells
were then washed, resuspended, and stained in PBS con-
taining 10 μg/ml propidium iodide (PI) and 1 μg/mlRNase A in PBS for 30 min at room temperature. Cell dis-
tribution across the cell cycle was analyzed with a CyAn
ADP flow cytometer (Dako Cytomation).
In vitro dimerization assay
Whole cell extracts of HEK293T cells containing FLAG-
STAT3 were prepared using ice-cold isotonic buffer
[20 mmol/L Tris (pH 7.0), 150 mmol/L NaCl, 6 mmol/L
MgCl2, 0.8 mmol/L PMSF, and 20% glycerol]. Homo-
genization of lysates was performed using a 30-gauge syr-
inge and then cleared by centrifugation at 13,000 rpm for
30 min at 4°C. Equal amounts of lysates were incubated
with increasing amounts of garcinol with DMSO as solvent
control at 30°C for 15 min. STAT3 dimers were identified
upon loading the treated lysates in a 10% SDS free PAGE
gel and immunblotted using FLAG antibody.
Electrophoretic mobility shift assay
Oligonucleotide derived from c-fos promoter containing
STAT3 binding sites was end labeled with [γ-32P] ATP
by T4 polynucleotide kinase (Merck Biosciences). Labeled
strand was then annealed with its complementary un-
labelled strand for the EMSA studies. FLAG-STAT3 was
affinity purified from HEK293T cells after transient
transfection of FLAG-STAT3 construct for 24 h and
was incubated with labeled oligo along with appropriate
concentration of garcinol for 20 min at 30°C. For supershift
validation, STAT3 antibody was added in the appropriate
sample and was incubated for another 20 min at 30°C. The
complexes were then run in a 5% native PAGE using 0.5X
Tris-borate-EDTA buffer. Gels were then dried and ex-
posed for autoradiography in a phosphoimager cassette.
Tumor model
All procedures involving animals were reviewed and
approved by NUS Institutional Animal Care and Use
Committee. Six week-old athymic nu/nu female mice
(Animal Resource Centre, Australia) were implanted
subcutaneously in the right flank with (3 × 106 PLC/PRF5
cells/100 μl saline). When tumors have reached 0.5 cm in
diameter, mice received intra-peritoneal injection of 1 mg/
kg and 2 mg/kg garcinol in 200 μl corn oil (n = 5) or corn
oil alone (n = 5), 5 doses per week for 3 consecutive weeks.
Animals were euthanized at day 22 after first therapeutic
dose injection. Tumor dimensions were measured using a
digital caliper, and the tumor volume (V) calculated using
the formula: V=π/6 X length X (width) 2. Growth curves
were plotted using average relative tumor volume within
each experimental group at the set time points.
Immunohistochemical (IHC) analysis of tumor samples
Solid tumors from control and garcinol treated mice were
fixed with 10% phosphate buffered formalin, processed and
embedded in paraffin. Sections were cut and deparafinized
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hydrated in water. Antigen retrieval was performed by
boiling the slide in 10 mM sodium citrate (pH 6.0) for
30 min. Immunohistochemistry was performed following
manufacturer instructions (DAKO LSAB kit).
Confocal Laser Microscopy
HepG2 cells were grown on polylysine-coated coverslips
for 24 h in the presence of Modified Eagle medium supple-
mented with 10% fetal bovine serum. Appropriate treat-
ments were given to cells. Then cells were washed with
1XPBS, fixed with 4% paraformaldehyde and permeabilized
with 0.5% Triton X-100. Anti-STAT3 (Abcam) antibody
was used as primary antibody and fluorescently labeled
anti-Rabbit Alexa-488 conjugated (Invitrogen) was used
as secondary antibody. Hoechst and Alexa fluorescence
were visualized using a Carl Zeiss confocal laser scanning
microscope (Axioskop 2 Plus).
Statistical analysis
Statistical analysis was performed by Student’s t-test and
one way analysis of variance, (ANOVA). A p value of less
than 0.05 was considered statistically significant.
Additional files
Additional file 1: Figure S1. Garcinol treatment suppressed nuclear
translocation of STAT3 in hyperacetylation background. HepG2 cells
grown on poly-lysine coated coverslips were incubated with 1mM NaBu
for 6hrs to induce the internal acetylation. Cells were then treated with
two different concentrations of garcinol (10μM and 25 μM) for 4hrs and
processed for confocal imaging using antibody against STAT3.
Additional file 2: Figure S2. Garcinol treatment suppressed nuclear
translocation of STAT3 in HepG2 cells: HepG2 cells were grown on
poly-lysine coated coverslips. Cells were then treated with either DMSO
or 10μM of garcinol for 3h and processed for confocal imaging after
immune-staining with antibody against STAT3.
Abbreviations
STAT3: Signal transducer and activator of transcription 3; HCC: Hepatocellular
carcinoma; FBS: Fetal bovine serum; MTT: 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyl-2H-tetrazolium bromide; JAK: Janus-like kinase.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JB has done isolation and characterization of garcinol. NN has done collection
and authentication of natural material. GS was involved in designing and
execution as well as supervision of work. SC, PS, AKB, GS were involved in cell
line based experiments, data analysis, also in the preparation of manuscript. PR,
FL, MKS, KFW, APK, and KMH were involved in different cell and animal based
experiments. JML and TKK have done overall supervision of work. All authors
read and approved the final version of manuscript.
Authors’ information
GS and SC are joint first authors.
Acknowledgments
This work was supported by grants from National Medical Research Council
of Singapore [Grant R-184-000-211-213] to GS. APK was supported by grants
from Singapore Ministry of Education Tier 2 [R-713-000-142-112], AcademicResearch Fund Tier 1 [R-184-000-228-112] and Cancer Science Institute of
Singapore, Experimental Therapeutics I Program [R-713-001-011-271]. TKK
was supported by grants from Department of Biotechnology, Govt. of India
(Chromatin and Disease: Programme support grant number BT/01/CEIB/10/III/01).
TKK is a recipient of the Sir J.C. Bose National Fellowship, Department of Science
and Technology, Government of India.
Author details
1Department of Pharmacology, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore 117597, Singapore. 2Cancer Science
Institute of Singapore, National University of Singapore, Singapore 117456,
Singapore. 3Jawaharlal Nehru Centre for Advanced Scientific Research,
Molecular Biology and Genetics Unit, Transcription and Disease Laboratory,
Jakkur P.O., Bangalore 560064, India. 4School of Biomedical Sciences, Faculty
of Health Sciences, Curtin University, Bentley, WA 6009, Australia.
5Department of Biological Sciences, University of North Texas, Denton, TX
76203, USA. 6Division of Cellular and Molecular Research, Humphrey Oei
Institute of Cancer Research, National Cancer Centre, Singapore 169610,
Singapore. 7Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos,
Singapore 138673, Singapore. 8Central Government Health Scheme
Dispensary, No. 3, Basavanagudi, Bangalore, India.
Received: 15 August 2013 Accepted: 12 March 2014
Published: 21 March 2014References
1. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in
the United States. N Engl J Med 1999, 340:745–750.
2. Bruix J, Boix L, Sala M, Llovet JM: Focus on hepatocellular carcinoma.
Cancer Cell 2004, 5:215–219.
3. Lupberger J, Hildt E: Hepatitis B virus-induced oncogenesis. World J
Gastroenterol 2007, 13:74–81.
4. Yau T, Chan P, Epstein R, Poon RT: Management of advanced hepatocellular
carcinoma in the era of targeted therapy. Liver Int 2009, 29:10–17.
5. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G: Current
management strategy of hepatocellular carcinoma. World J Gastroenterol
2009, 15:3210–3216.
6. Ihle JN: STATs: signal transducers and activators of transcription. Cell
1996, 84:331–334.
7. Costantino L, Barlocco D: STAT 3 as a target for cancer drug discovery.
Curr Med Chem 2008, 15:834–843.
8. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca
C, Dey S, Sung B: Signal transducer and activator of transcription-3,
inflammation, and cancer: how intimate is the relationship? Ann N Y Acad
Sci 2009, 1171:59–76.
9. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B,
Ichikawa H: Targeting signal-transducer-and-activator-of-transcription-3 for
prevention and therapy of cancer: modern target but ancient solution. Ann N
Y Acad Sci 2006, 1091:151–169.
10. Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X,
Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM, Sethi G: Potential role of
signal transducer and activator of transcription (STAT)3 signaling
pathway in inflammation, survival, proliferation and invasion of
hepatocellular carcinoma. Biochim Biophys Acta 1835, 2013:46–60.
11. Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen L, Vali S,
Abbasi T, Kapoor S, Ahn KS, Kumar AP, Hui KM, Sethi G: Emodin inhibits
growth and induces apoptosis in an orthotopic hepatocellular
carcinoma model by blocking activation of STAT3. Br J Pharmacol 2013,
170:807–821.
12. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, Abbasi T,
Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G: Suppression of signal
transducer and activator of transcription 3 activation by butein
inhibits growth of human hepatocellular carcinoma in vivo.
Clin Cancer Res 2011, 17:1425–1439.
13. Yuan ZL, Guan YJ, Chatterjee D, Chin YE: Stat3 dimerization regulated by
reversible acetylation of a single lysine residue. Science 2005, 307:269–273.
14. Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z, Hoon DS, Forman SJ,
Jove R, Riggs AD, Yu H: Acetylated STAT3 is crucial for methylation of
tumor-suppressor gene promoters and inhibition by resveratrol results
in demethylation. Proc Natl Acad Sci U S A 2012, 109:7765–7769.
Sethi et al. Molecular Cancer 2014, 13:66 Page 14 of 14
http://www.molecular-cancer.com/content/13/1/6615. Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP,
Kundu TK: Polyisoprenylated benzophenone, garcinol, a natural histone
acetyltransferase inhibitor, represses chromatin transcription and alters global
gene expression. J Biol Chem 2004, 279:33716–33726.
16. Padhye S, Ahmad A, Oswal N, Sarkar FH: Emerging role of Garcinol, the
antioxidant chalcone from Garcinia indica Choisy and its synthetic
analogs. J Hematol Oncol 2009, 2:38.
17. Arif M, Pradhan SK, Thanuja GR, Vedamurthy BM, Agrawal S, Dasgupta D,
Kundu TK: Mechanism of p300 specific histone acetyltransferase
inhibition by small molecules. J Med Chem 2009, 52:267–277.
18. Hong J, Kwon SJ, Sang S, Ju J, Zhou JN, Ho CT, Huang MT, Yang CS: Effects
of garcinol and its derivatives on intestinal cell growth: Inhibitory effects
and autoxidation-dependent growth-stimulatory effects. Free Radic Biol
Med 2007, 42:1211–1221.
19. Parasramka MA, Gupta SV: Garcinol inhibits cell proliferation and promotes
apoptosis in pancreatic adenocarcinoma cells. Nutr Cancer 2011, 63:456–465.
20. Yamaguchi F, Saito M, Ariga T, Yoshimura Y, Nakazawa H: Free radical
scavenging activity and antiulcer activity of garcinol from Garcinia indica
fruit rind. J Agric Food Chem 2000, 48:2320–2325.
21. Chatterjee A, Yasmin T, Bagchi D, Stohs SJ: The bactericidal effects of
Lactobacillus acidophilus, garcinol and Protykin compared to
clarithromycin, on Helicobacter pylori. Mol Cell Biochem 2003, 243:29–35.
22. Liao CH, Ho CT, Lin JK: Effects of garcinol on free radical generation and
NO production in embryonic rat cortical neurons and astrocytes.
Biochem Biophys Res Commun 2005, 329:1306–1314.
23. Liao CH, Sang S, Ho CT, Lin JK: Garcinol modulates tyrosine
phosphorylation of FAK and subsequently induces apoptosis through
down-regulation of Src, ERK, and Akt survival signaling in human colon
cancer cells. J Cell Biochem 2005, 96:155–169.
24. Hong J, Sang S, Park HJ, Kwon SJ, Suh N, Huang MT, Ho CT, Yang CS:
Modulation of arachidonic acid metabolism and nitric oxide synthesis by
garcinol and its derivatives. Carcinogenesis 2006, 27:278–286.
25. Padhye S, Ahmad A, Oswal N, Dandawate P, Rub RA, Deshpande J, Swamy
KV, Sarkar FH: Fluorinated 2'-hydroxychalcones as garcinol analogs with
enhanced antioxidant and anticancer activities. Bioorg Med Chem Lett
2010, 20:5818–5821.
26. Prasad S, Ravindran J, Sung B, Pandey MK, Aggarwal BB: Garcinol
potentiates TRAIL-induced apoptosis through modulation of death
receptors and antiapoptotic proteins. Mol Cancer Ther 2010, 9:856–868.
27. Chen CS, Lee CH, Hsieh CD, Ho CT, Pan MH, Huang CS, Tu SH, Wang YJ,
Chen LC, Chang YJ, Wei PL, Yang YY, Wu CH, Ho YS: Nicotine-induced
human breast cancer cell proliferation attenuated by garcinol through
down-regulation of the nicotinic receptor and cyclin D3 proteins.
Breast Cancer Res Treat 2011, 125:73–87.
28. Ahmad A, Wang Z, Wojewoda C, Ali R, Kong D, Maitah MY, Banerjee S, Bao
B, Padhye S, Sarkar FH: Garcinol-induced apoptosis in prostate and
pancreatic cancer cells is mediated by NF- KappaB signaling. Front Biosci
(Elite Ed) 2011, 3:1483–1492.
29. Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, Wang
W, Khin E, Tergaonkar V, Kumar AP, Luk JM, Sethi G: Celastrol suppresses
growth and induces apoptosis of human hepatocellular carcinoma
through the modulation of STAT3/JAK2 signaling cascade in vitro and
in vivo. Cancer Prev Res (Phila) 2012, 5:631–643.
30. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS,
Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM: Inhibition of acute
lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379:645–648.
31. Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene
2000, 19:2474–2488.
32. Moran DM, Mattocks MA, Cahill PA, Koniaris LG, McKillop IH: Interleukin-6
mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a
STAT3-dependent pathway. J Surg Res 2008, 147:23–33.
33. Zauberman A, Zipori D, Krupsky M, Ben-Levy R: Stress activated protein
kinase p38 is involved in IL-6 induced transcriptional activation of STAT3.
Oncogene 1999, 18:3886–3893.
34. Becker S, Groner B, Muller CW: Three-dimensional structure of the
Stat3beta homodimer bound to DNA. Nature 1998, 394:145–151.
35. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN,
Bourne PE: The Protein Data Bank. Nucleic Acids Res 2000, 28:235–242.
36. Wang R, Cherukuri P, Luo J: Activation of Stat3 sequence-specific DNA
binding and transcription by p300/CREB-binding protein-mediated
acetylation. J Biol Chem 2005, 280:11528–11534.37. Arif M, Vedamurthy BM, Choudhari R, Ostwal YB, Mantelingu K, Kodaganur
GS, Kundu TK: Nitric oxide-mediated histone hyperacetylation in oral
cancer: target for a water-soluble HAT inhibitor, CTK7A. Chem Biol 2010,
17:903–913.
38. Yokomizo C, Yamaguchi K, Itoh Y, Nishimura T, Umemura A, Minami M,
Yasui K, Mitsuyoshi H, Fujii H, Tochiki N, Nakajima T, Okanoue T, Yoshikawa
T: High expression of p300 in HCC predicts shortened overall survival in
association with enhanced epithelial mesenchymal transition of HCC
cells. Cancer Lett 2011, 310:140–147.
39. Jin C, Li H, He Y, He M, Bai L, Cao Y, Song W, Dou K: Combination
chemotherapy of doxorubicin and paclitaxel for hepatocellular
carcinoma in vitro and in vivo. J Cancer Res Clin Oncol 2010, 136:267–274.
40. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM:
Cryptotanshinone inhibits constitutive signal transducer and activator of
transcription 3 function through blocking the dimerization in DU145
prostate cancer cells. Cancer Res 2009, 69:193–202.
41. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, Pellegrini S,
Yasukawa K, Heinrich P, Stark GR: A major role for the protein tyrosine
kinase JAK1 in the JAK/STAT signal transduction pathway in response to
interleukin-6. EMBO J 1995, 14:1421–1429.
42. Liu Y, Liu A, Li H, Li C, Lin J: Celecoxib Inhibits Interleukin-6/Interleukin-6
Receptor-Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular
Carcinoma Cells. Cancer Prev Res (Phila). 2011, 4:1296–1305.
43. Collins HM, Abdelghany MK, Messmer M, Yue B, Deeves SE, Kindle KB,
Mantelingu K, Aslam A, Winkler GS, Kundu TK, Heery DM: Differential
effects of garcinol and curcumin on histone and p53 modifications in
tumour cells. BMC Cancer 2013, 13:37.
44. Mantelingu K, Reddy BA, Swaminathan V, Kishore AH, Siddappa NB, Kumar
GV, Nagashankar G, Natesh N, Roy S, Sadhale PP, Ranga U, Narayana C,
Kundu TK: Specific inhibition of p300-HAT alters global gene expression
and represses HIV replication. Chem Biol 2007, 14:645–657.
45. Li F, Shanmugam MK, Chen L, Chatterjee S, Basha J, Kumar AP, Kundu TK,
Sethi G: Garcinol, a polyisoprenylated benzophenone modulates multiple
proinflammatory signaling cascades leading to the suppression of
growth and survival of head and neck carcinoma. Cancer Prev Res (Phila).
2013, 6:843–854.
46. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair
AS, Shishodia S, Aggarwal BB: Resveratrol inhibits proliferation, induces
apoptosis, and overcomes chemoresistance through down-regulation of
STAT3 and nuclear factor-κB-regulated antiapoptotic and cell survival gene
products in human multiple myeloma cells. Blood 2007, 109:2293–2302.
47. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N,
Morris S, Skorski T, Wasik MA: Multilevel dysregulation of STAT3 activation
in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol
2002, 168:466–474.
48. Ahmad A, Wang Z, Ali R, Maitah MY, Kong D, Banerjee S, Padhye S, Sarkar
FH: Apoptosis-inducing effect of garcinol is mediated by NF-kappaB
signaling in breast cancer cells. J Cell Biochem 2010, 109:1134–1141.
49. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R,
Pardoll DM, Yu H: Persistently activated Stat3 maintains constitutive
NF-kappaB activity in tumors. Cancer Cell 2009, 15:283–293.
50. Ahmad A, Sarkar SH, Aboukameel A, Ali S, Biersack B, Seibt S, Li Y, Bao B,
Kong D, Banerjee S, Schobert R, Padhye SB, Sarkar FH: Anticancer action of
garcinol in vitro and in vivo is in part mediated through inhibition of
STAT-3 signaling. Carcinogenesis 2012, 33:2450–2456.
51. Tanaka T, Kohno H, Shimada R, Kagami S, Yamaguchi F, Kataoka S, Ariga T,
Murakami A, Koshimizu K, Ohigashi H: Prevention of colonic aberrant crypt
foci by dietary feeding of garcinol in male F344 rats. Carcinogenesis 2000,
21:1183–1189.
52. Yoshida K, Tanaka T, Hirose Y, Yamaguchi F, Kohno H, Toida M, Hara A, Sugie S,
Shibata T, Mori H: Dietary garcinol inhibits 4-nitroquinoline 1-oxide-induced
tongue carcinogenesis in rats. Cancer Lett 2005, 221:29–39.
53. Huang J, Plass C, Gerhauser C: Cancer Chemoprevention by Targeting the
Epigenome. Curr Drug Targets 2010, 12:1925–1956.
doi:10.1186/1476-4598-13-66
Cite this article as: Sethi et al.: Inhibition of STAT3 dimerization and
acetylation by garcinol suppresses the growth of human hepatocellular
carcinoma in vitro and in vivo. Molecular Cancer 2014 13:66.
